AnaptysBio stock analysis
AnaptysBio (AN6) Stock Price & Analysis
AN6 Stock Chart & Stats
- Day’s Range
- EUR 42.91 - EUR 43.42
- 52-Week Range
- EUR 28.40 - EUR 61.48
- Previous Close
- EUR 43.74
- Volume
- N/A
- Average Volume (3M)
- 16
- Market Cap
- EUR 1.30B
- Enterprise Value
- EUR 1.87B
- Total Cash (Recent Filing)
- EUR 152.99M
- Total Debt (Recent Filing)
- EUR 12.57M
- Price to Earnings (P/E)
- 7.3
- Beta
- 0.43
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Current Profitability
The latest results show a substantial profitability inflection, with strong net income and operating margins. If this earnings improvement is supported by collaboration economics and licensing activity, it can provide meaningful internal funding capacity and improve strategic flexibility over the next several quarters.
Cash Generation Turnaround
Positive operating and free cash flow represent a material improvement from the company’s earlier cash-burning period. Strong cash conversion in the latest TTM can reduce reliance on external financing and provide greater flexibility to advance antibody programs or pursue partnerships.
Antibody Platform And Partnering Model
An antibody discovery and engineering platform gives AnaptysBio a defined basis for developing biologic candidates in immune and inflammatory diseases. Its ability to partner or out-license programs also provides a route to monetize development work without relying solely on future product sales.
Bears Say
Revenue Contraction
Revenue contraction weakens confidence that the latest profit level represents a steadily expanding operating base. For a company relying on collaboration and licensing economics, lower revenue can signal uneven deal timing or reduced commercial contribution, making future earnings and cash generation less predictable.
Thin Equity Cushion
The very small equity base leaves the company financially sensitive to changes in reported equity, even though absolute debt is relatively low. This thin cushion can constrain capital allocation and increase financial fragility if operating results weaken or additional funding becomes necessary.
History Of Cash Burn
The recent cash-flow improvement has not yet established a long, stable record of self-funding. Prior multi-year cash burn indicates that operating performance can be highly variable, which may require renewed reliance on collaborations or external financing if profitability and cash conversion deteriorate.
AN6 FAQ
What was AnaptysBio’s price range in the past 12 months?
What is AnaptysBio’s market cap?
When is AnaptysBio’s upcoming earnings report date?
How were AnaptysBio’s earnings last quarter?
Is AnaptysBio overvalued?
Does AnaptysBio pay dividends?
What is AnaptysBio’s EPS estimate?
How many shares outstanding does AnaptysBio have?
What happened to AnaptysBio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AnaptysBio?
What is the TipRanks Smart Score and how is it calculated?
AnaptysBio Stock Smart Score
Company Description
AnaptysBio
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Faga
- Employees
- 104
- Website
- www.anaptysbio.com
- Address
- 10770 Wateridge Circle, San Diego, CA, 92121, US
AnaptysBio (AN6) Earnings & Revenues
AN6 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 4 | 9 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 6 | 0 | 6 |
